tiprankstipranks
Centene (GB:0HVB)
LSE:0HVB
UK Market
0HVB
Centene
RESEARCH TOOLSreports

Centene (0HVB) Share Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0HVB Analyst Ratings

Moderate Buy
15Ratings
Moderate Buy
6 Buy
9 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Centene
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HVB Stock 12 Month Forecast

Average Price Target

$72.50
▲(17.50% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Centene in the last 3 months. The average price target is $72.50 with a high forecast of $80.00 and a low forecast of $65.00. The average price target represents a 17.50% change from the last price of $61.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","81":"$81","38.25":"$38.3","52.5":"$52.5","66.75":"$66.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$72.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,38.25,52.5,66.75,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.055,63.43538461538461,64.81576923076923,66.19615384615385,67.57653846153846,68.95692307692308,70.33730769230769,71.7176923076923,73.09807692307692,74.47846153846154,75.85884615384616,77.23923076923077,78.61961538461539,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.055,62.85846153846154,63.661923076923074,64.46538461538462,65.26884615384616,66.07230769230769,66.87576923076924,67.67923076923077,68.4826923076923,69.28615384615385,70.08961538461539,70.89307692307692,71.69653846153847,{"y":72.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.055,62.28153846153846,62.50807692307692,62.73461538461538,62.96115384615385,63.18769230769231,63.41423076923077,63.64076923076923,63.86730769230769,64.09384615384616,64.32038461538461,64.54692307692308,64.77346153846153,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.881,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.622,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.82,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.45,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.615,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.891,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.02,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.86,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.41,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.055,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$80.00Average Price Target$72.50Lowest Price Target$65.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on GB:0HVB
John Stansel
J.P. Morgan
J.P. Morgan
$67
Hold
8.59%
Upside
Assigned
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioNTech SE (NASDAQ: BNTX) and Centene (NYSE: CNC)
Barclays Analyst forecast on GB:0HVB
Andrew Mok CFA
Barclays
Barclays
$80
Buy
29.66%
Upside
Reiterated
08/18/26
Barclays Sticks to Its Buy Rating for Centene (CNC)
Bernstein Analyst forecast on GB:0HVB
Lance Wilkes
Bernstein
Bernstein
$79
Buy
28.04%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (NASDAQ: CLRB), NeuroOne Medical Technologies (NASDAQ: NMTC) and Centene (NYSE: CNC)
Argus Research Analyst forecast on GB:0HVB
John Staszak
Argus Research
Argus Research
$80
Buy
29.66%
Upside
Upgraded
08/10/26
Centene upgraded to Buy from Hold at ArgusCentene upgraded to Buy from Hold at Argus
TD Cowen Analyst forecast on GB:0HVB
Ryan Langston
TD Cowen
TD Cowen
$65
Hold
5.35%
Upside
Assigned
07/30/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Centene (NYSE: CNC) and Dyne Therapeutics (NASDAQ: DYN)
Morgan Stanley Analyst forecast on GB:0HVB
Erin Wright
Morgan Stanley
Morgan Stanley
$57→$66
Hold
6.97%
Upside
Reiterated
07/29/26
Erin Wright Raises Centene Price Target to $66 on Strong Execution but Maintains Hold Amid Sustainability Concerns
Truist Financial Analyst forecast on GB:0HVB
David S Macdonald
Truist Financial
Truist Financial
$78→$80
Buy
29.66%
Upside
Reiterated
07/29/26
Truist Financial Keeps Their Buy Rating on Centene (CNC)
UBS Analyst forecast on GB:0HVB
A.J. Rice
UBS
UBS
$61→$70
Hold
13.45%
Upside
Reiterated
07/29/26
Centene price target raised to $70 from $61 at UBSCentene price target raised to $70 from $61 at UBS
Robert W. Baird Analyst forecast on GB:0HVB
Michael Ha
Robert W. Baird
Robert W. Baird
$46→$66
Hold
6.97%
Upside
Reiterated
07/29/26
Centene price target raised to $66 from $46 at Baird Centene price target raised to $66 from $46 at Baird
RBC Capital Analyst forecast on GB:0HVB
Ben Hendrix
RBC Capital
RBC Capital
$71
Hold
15.07%
Upside
Reiterated
07/28/26
RBC Capital Reaffirms Their Hold Rating on Centene (CNC)
Cantor Fitzgerald Analyst forecast on GB:0HVB
Sarah James
Cantor Fitzgerald
Cantor Fitzgerald
$75
Buy
21.56%
Upside
Reiterated
07/28/26
Analysts Are Bullish on These Healthcare Stocks: Centene (CNC), Ansell (ANSLF)
Guggenheim Analyst forecast on GB:0HVB
Jason Cassorla
Guggenheim
Guggenheim
―
Hold
―
Reiterated
07/28/26
Guggenheim Sticks to Its Hold Rating for Centene (CNC)
Bank of America Securities Analyst forecast on GB:0HVB
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$78
Buy
26.42%
Upside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Centene (NYSE: CNC), Incyte (NASDAQ: INCY) and IQVIA Holdings (NYSE: IQV)
Mizuho Securities Analyst forecast on GB:0HVB
Ann Hynes
Mizuho Securities
Mizuho Securities
$63→$69
Hold
11.83%
Upside
Reiterated
07/13/26
Mizuho Securities Remains a Hold on Centene (CNC)
Wells Fargo Analyst forecast on GB:0HVB
Stephen Baxter
Wells Fargo
Wells Fargo
$56→$69
Hold
11.83%
Upside
Reiterated
07/13/26
Centene price target raised to $69 from $56 at Wells FargoCentene price target raised to $69 from $56 at Wells Fargo
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on GB:0HVB
John Stansel
J.P. Morgan
J.P. Morgan
$67
Hold
8.59%
Upside
Assigned
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioNTech SE (NASDAQ: BNTX) and Centene (NYSE: CNC)
Barclays Analyst forecast on GB:0HVB
Andrew Mok CFA
Barclays
Barclays
$80
Buy
29.66%
Upside
Reiterated
08/18/26
Barclays Sticks to Its Buy Rating for Centene (CNC)
Bernstein Analyst forecast on GB:0HVB
Lance Wilkes
Bernstein
Bernstein
$79
Buy
28.04%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (NASDAQ: CLRB), NeuroOne Medical Technologies (NASDAQ: NMTC) and Centene (NYSE: CNC)
Argus Research Analyst forecast on GB:0HVB
John Staszak
Argus Research
Argus Research
$80
Buy
29.66%
Upside
Upgraded
08/10/26
Centene upgraded to Buy from Hold at ArgusCentene upgraded to Buy from Hold at Argus
TD Cowen Analyst forecast on GB:0HVB
Ryan Langston
TD Cowen
TD Cowen
$65
Hold
5.35%
Upside
Assigned
07/30/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Centene (NYSE: CNC) and Dyne Therapeutics (NASDAQ: DYN)
Morgan Stanley Analyst forecast on GB:0HVB
Erin Wright
Morgan Stanley
Morgan Stanley
$57→$66
Hold
6.97%
Upside
Reiterated
07/29/26
Erin Wright Raises Centene Price Target to $66 on Strong Execution but Maintains Hold Amid Sustainability Concerns
Truist Financial Analyst forecast on GB:0HVB
David S Macdonald
Truist Financial
Truist Financial
$78→$80
Buy
29.66%
Upside
Reiterated
07/29/26
Truist Financial Keeps Their Buy Rating on Centene (CNC)
UBS Analyst forecast on GB:0HVB
A.J. Rice
UBS
UBS
$61→$70
Hold
13.45%
Upside
Reiterated
07/29/26
Centene price target raised to $70 from $61 at UBSCentene price target raised to $70 from $61 at UBS
Robert W. Baird Analyst forecast on GB:0HVB
Michael Ha
Robert W. Baird
Robert W. Baird
$46→$66
Hold
6.97%
Upside
Reiterated
07/29/26
Centene price target raised to $66 from $46 at Baird Centene price target raised to $66 from $46 at Baird
RBC Capital Analyst forecast on GB:0HVB
Ben Hendrix
RBC Capital
RBC Capital
$71
Hold
15.07%
Upside
Reiterated
07/28/26
RBC Capital Reaffirms Their Hold Rating on Centene (CNC)
Cantor Fitzgerald Analyst forecast on GB:0HVB
Sarah James
Cantor Fitzgerald
Cantor Fitzgerald
$75
Buy
21.56%
Upside
Reiterated
07/28/26
Analysts Are Bullish on These Healthcare Stocks: Centene (CNC), Ansell (ANSLF)
Guggenheim Analyst forecast on GB:0HVB
Jason Cassorla
Guggenheim
Guggenheim
―
Hold
―
Reiterated
07/28/26
Guggenheim Sticks to Its Hold Rating for Centene (CNC)
Bank of America Securities Analyst forecast on GB:0HVB
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$78
Buy
26.42%
Upside
Reiterated
07/28/26
Analysts Offer Insights on Healthcare Companies: Centene (NYSE: CNC), Incyte (NASDAQ: INCY) and IQVIA Holdings (NYSE: IQV)
Mizuho Securities Analyst forecast on GB:0HVB
Ann Hynes
Mizuho Securities
Mizuho Securities
$63→$69
Hold
11.83%
Upside
Reiterated
07/13/26
Mizuho Securities Remains a Hold on Centene (CNC)
Wells Fargo Analyst forecast on GB:0HVB
Stephen Baxter
Wells Fargo
Wells Fargo
$56→$69
Hold
11.83%
Upside
Reiterated
07/13/26
Centene price target raised to $69 from $56 at Wells FargoCentene price target raised to $69 from $56 at Wells Fargo
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Centene

3 Months
Lance WilkesBernstein
Success Rate
16/23 ratings generated profit
70%
Average Return
+9.57%
Copying Lance Wilkes's trades and holding each position for 3 Months would result in 69.57% of your transactions generating a profit, with an average return of +9.57% per trade.
1 Year
Kevin FischbeckBank of America Securities
Success Rate
16/23 ratings generated profit
70%
Average Return
+0.95%
Copying Kevin Fischbeck's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +0.95% per trade.
2 Years
Lance WilkesBernstein
Success Rate
17/23 ratings generated profit
74%
Average Return
+33.24%
Copying Lance Wilkes's trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +33.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HVB Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
2
2
0
0
0
Buy
13
12
17
16
16
Hold
16
14
15
20
17
Sell
5
4
3
0
0
Strong Sell
0
0
0
0
0
total
36
32
35
36
33
In the current month, 0HVB has received 16 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. 0HVB average Analyst price target in the past 3 months is 72.50.
Each month's total comprises the sum of three months' worth of ratings.

0HVB Financial Forecast

0HVB Earnings Forecast

Next quarter’s earnings estimate for 0HVB is $0.10 with a range of $0.00 to $0.33. The previous quarter’s EPS was $2.51. 0HVB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HVB has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0HVB is $0.10 with a range of $0.00 to $0.33. The previous quarter’s EPS was $2.51. 0HVB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HVB has Performed in-line its overall industry.

0HVB Sales Forecast

Next quarter’s sales forecast for 0HVB is $47.11B with a range of $45.63B to $49.17B. The previous quarter’s sales results were $53.58B. 0HVB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HVB has Performed in-line its overall industry.
Next quarter’s sales forecast for 0HVB is $47.11B with a range of $45.63B to $49.17B. The previous quarter’s sales results were $53.58B. 0HVB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HVB has Performed in-line its overall industry.

0HVB Stock Forecast FAQ

What is GB:0HVB’s average 12-month price target, according to analysts?
Based on analyst ratings, Centene’s 12-month average price target is 72.50.
    What is GB:0HVB’s upside potential, based on the analysts’ average price target?
    Centene has 17.50% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Centene a Buy, Sell or Hold?
          Centene has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 9 hold ratings and 0 sell ratings.
            What is Centene’s share price target?
            The average share price target for Centene is 72.50. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $80.00 ,and the lowest forecast is $65.00. The average share price target represents 17.50% Increase from the current price of $61.7.
              What do analysts say about Centene?
              Centene’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of Centene?
                To buy shares of GB:0HVB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.